Are animal models of vasculitis suitable tools?

Current Opinion in Rheumatology

Volumn 12, Issue 1, 2000, Pages 11-19

  Specks, Ulrich ^a,b  

^a MAYO CLINIC   (United States)

^b Thoracic Diseases Research Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN PEROXIDE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANIMAL MODEL; AUTOIMMUNITY; CHIMERA; GENETIC PREDISPOSITION; GIANT CELL ARTERITIS; GLOMERULONEPHRITIS; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNITY; CHIMERA; DISEASE MODELS, ANIMAL; GLOMERULONEPHRITIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MERCURIC CHLORIDE; MICE; MICE, INBRED MRL LPR; RATS; VASCULITIS;

EID: 0033986121     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200001000-00003     Document Type: Review

References (59)

1. 1 Dal Canto AJ, Virgin HW: Animal models of infection-mediated vasculitis. Curr Opin Rheumatol 1999, 11:17-23.
2. 2 Watanabe-Fukunaga R, Brannann CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317.
3. 3 Mountz JD, Zhou T, Buethmann H, Wu J, Edwards CK III: Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice. Intern Rev Immunol 1994, 11:321-342.
4. 4 Rose LM, Latchman DS, Isenberg DA: Elevated soluble fas production in SLE correlates with HLA status not with disease activity. Lupus 1997, 6:717-722.
5. 5 Mysler E, Bini P, Drappa J, Ramos P, Friedman SM, Krammer PH, Elkon FB: The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994, 93:1029-1034.
6. 6 Huggins ML, Huang F-P, Xu D, Lindop G, Stott DI: Modulation of autoimmune disease in the MRL-lpr/lpr mouse by IL-2 and TGF-β1 gene therapy using attenuated Salmonella typhimurium as gene carrier. Lupus 1999, 8:29-38. This study demonstrates the feasability of a novel convenient gene therapy approach based on understanding of underlying pathomechanisms, and points out the crucial influence of vector and route of application for the result of gene therapeutic intervention.
7. 7 Raz E, Dudler J, Lotz M, Baird SM, Berry CC, Eisenberg RA, Carson DA: Modulation of disease activity in murine systemic erythematosus by cytokine gene delivery. Lupus 1995, 4:286-292.
8. 8 Gutierrez-Ramos JC, Andreu JL, Revilla Y, Vinuela E, Martinez C: Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature 1990, 346:271-274.
9. 9 Nose M, Nishimura M, Ito MR, Itoh J, Shibata T, Sugisaki T: Arteritis in a novel congenic strain of mice derived from MRL/lpr lupus mice. Am J Path 1996, 149:1763-1769.
10. 10 Watson ML, Rao JK, Gilkeson GS, Ruiz P, Eicher EM, Pisetsky DS, Matsuzawa A, Rochelle JM, Seldin MF: Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med 1992, 176:1645-1656.
11. 11 Wang Y, Nose M, Kamoto T, Nishimura M, Hiai H: Host modifier genes affect mouse autoimmunity induced by the lpr gene. Am J Pathol 1997, 151:1791-1798.
12. 12 Vidal S, Kono DH, Theofilopoulos AN: Loci predisposing to autoimmunity in MRL-Faslpr mice. J Clin Invest 1998, 101:696-702.
13. 13 Gu L, Weinreb A, Wang XP, Zack DJ, Qiao JH, Weisbart R, Lusis AJ: Genetic determinants of autoimmune disease and coronary vasculitis in the MRL-1prl 1pr mouse model of systemic lupus erythematosus. J Immunol 1998, 161:6999-7006.
14. 14 Kinjoh K, Kyogoku M, Good RA: Genetic selection for crescent formation yields mouse strain with rapidly progressive glomerulonephritis and small vessel vasculitis. Proc Natl Acad Sci USA 1993, 90:3413-3417.
15. 15 Cherry NN, Engelman RW, Wang BY, Kin joh K, El-Badri NS, Good RA: Prevention of crescentic glomerulonephritis in SCG/Kj mice by bone marrow transplantation. Proc Soc Exp Biol Med 1998, 218:223-228. This study implies that the molecular genetic lesions responsible for this immunologically based disease reside in the hematopoetic stem cell compartment, and provides further rationale for the use of bone marrow transplantation to treat certain autoimmune diseases.
16. 16 Cherry NN, Engelman RW, Wang BY, Kinjoh K, El-Badri NS, Good RA: Calorie restriction delays the crescentic glomerulonephritis of SCG/Kj mice. Proc Soc Exp Biol Med 1998, 218:218-222.
17. 17 Harper JM, Thiru S, Lockwood CM, Cooke A: Myeloperoxidase autoantibodies distinguish vasculitis mediated by anti-neutrophil cytoplasm antibodies from immune complex disease in MRL/Mp-lpr/lpr mice: a spontaneous model for human microscopic angiitis. Eur J Immunol 1998, 28:2217-2226. This study indicates that the presence of MPO-ANCA modulates the disease phenotype. In addition, treatment with antimicrobial agents attenuated the severity of vasculitic lesions, implying a contributory role of infections in the pathogenesis of vasculitis.
18. 18 Pusey CD, Bowman C, Morgan A, Weetman AP, Hartley B, Lockwood CM: Kinetics and pathogenicity of autoantibodies induced by mercuric chloride in the brown Norway rat. Clin Exp Immunol 1990, 81:76-82.
19. 19 Esnault VLM, Mathieson PW, Thiru S, Oliveira DBG, Martin-Lockwood C: Autoantibodies to myeloperoxidase in brown Norway rats treated with mercuric chloride. Lab Invest 1992, 67:114-120.
20. 20 Marriott JB, Qasim F, Oliveira DBG: Anti-phospholipid antibodies in the mercuric chloride treated Brown Norway rat. J Autoimmun 1994, 7:457-467.
21. 21 Mathieson PW, Thiru S, Oliveira DB: Mercuric chloride-treated brown Norway rats develop widespread tissue injury including necrotizing vasculitis. Lab Invest 1992, 67:121-129.
22. d mice is mediated by interferon-gamma (IFN-γ). Clin Exp Immunol 1997, 109:149-156.
23. 23 Qasim FJ, Mathieson PW, Thiru S, Oliveira DB, Lockwood CM: Further characterization of an animal model of systemic vasculitis. Adv Exp Med Biol 1993, 336:133-137.
24. + T cells revealed by in vivo depletion studies. Eur J Immunol 1991, 21:2105-2109.
25. high T cells in mercury-induced autoimmunity in the Brown Norway rat. J Exp Med 1993, 177:1309-1316.
26. 26 Qasim FJ, Mathieson PW, Thiru S, Oliveira DB: Cyclosporin A exacerbates mercuric chloride-induced vasculitis in the Brown Norway rat. Lab Invest 1995, 72:183-190.
27. 27 Qasim FJ, Thiru S, Mathieson PW, Oliveira DBG: The time course and characterization of mercuric chloride-induced immunopathology in the Brown Norway rat. J Autoimmun 1995, 8:193-208.
28. 28 Kiely PDW, Pecht I, Oliveira DBG: Mercuric chloride-induced vasculitis in the Brown Norway rat: αβ T cell-dependent and independent phases. J Immunol 1997, 159:5100-5106.
29. 29 Gillespie KM, Qasim FJ, Tibbatts LM, Thiru S, Oliveira DBG: Interleukin-4 gene expression in mercury-induced autoimmunity. Scand J Immunol 1995, 41:268-272.
30. 30 Oliveira DBG, Gillespie K, Wolfreys K, Mathieson PW, Qasim F, Coleman JW: Compounds that induce autoimmunity in the Brown Norway rat sensitize mat cells for mediator release and interleukin-4 expression. Eur J Immunol 1995, 25:2259-2264.
31. 31 Brouwer E, Huitema MG, Klok PA, de Weerd H, Tervaert JW, Weening JJ, Kallenberg CG: Anti-myeloperoxidase associated proliferative glomerulonephritis; an animal model. J Exp Med 1993, 177:905-914.
32. 32 Brouwer E, Klok PA, Huitema MG, Weening JJ, Kallenberg CGM: Renal ischemia/reperfusion injury contributes to renal damage in experimental anti-myeloperoxidae-associated proliferate glomerlonephritis. Kidney Int 1995, 47:1121-1129.
33. 33 Yang JJ, Jennette JC, Falk RJ: Immune complex glomerulonephritis is induced in rats immunized with heterologous myeloperoxidase. Clin Exp Immunol 1994, 97:466-473.
34. 34 Heeringa P, Brouwer E, Klok PA, Huitema MG, van den Born J, Weening JJ, Kallenberg CG: Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane mediated glomerular injury. Am J Pathol 1996, 149:1695-1706.
35. 2 in myeloperoxidae-immunized rats leads to necrotizing vasculitis in the lungs and gut. Am J Pathol 1997, 151:131-140.
36. 36 Heeringa P, van Goor H, Moshage H, Klok PA, Huitema MG, de Jager A. Schep AJ, Kallenberg CG: Expression of iNOS, eNos, and peroxynitrite-modified proteins in experimental anti-myeloperoxidase associated crescentic glomerulonephritis. Kidney Int 1998, 53:382-393.
37. 37 Foucher P, Heeringa P, Petersen AH, Huitema MG, Brouwer E, Cohen Tervaert JW, Prop J, Camus P, Weening JJ, Kallenberg CG: Anti-myeloperoxidase-associated lung disease: an experimental model. Am J Respir Crit Care Med 1999, 160:987-994. This recent study confirms that immunization of Brown Norway rats with human MPO reproducibly results in circulating rat anti-human MPO antibodies that crossreact with rat MPO, and that localized tissue perfusion with neutrophil granule extracts results in tissue injury at the site of reperfusion, ie, in this case in the lung.
38. 38 Kobayashi K, Shibata T, Sugisaki S: Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxidase antibodies. Kidney Int 1995, 47:454-463.
39. 39 Short AK, Esnault VLM, Lockwood CM: Anti-neutrophil cytoplasm antibodies and anti-glomerular basement membrane antibodies: two coexisting distinct autoreactivities detectable in patients with rapidly progressive glomerulonephritis. Am J Kidney Dis 1995, 26:439-445.
40. 40 Jayne DRW, Marshall PD, Jones SJ, Lockwood CM: Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 1990, 37:956-970.
41. 41 Bosch X, Mirapeix E, Font J, Borrellas X, Rodriguez R, Lopez-Soto A, Ingelmo M, Revert L: Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol 1991, 36:107-113.
42. 42 Bygren P, Rasmussen N, Isaksson B, Wieslander J: Anti-neutrophil cytoplasm antibodies, anti-GBM antibodies and anti-dsDNA antibodies in glomerulonephrtitis. Eur J Clin Invest 1992, 22:783-792.
43. 43 Brooks CJ, King WJ, Radford DJ, Adu D, McGrath M, Savage COS: IL-1b production by human polymorphonuclear leucocytes stimulated by anti-neutrophil cytoplasmic autoantibodies: relevance to systemic vasculitis. Clin Exp Immunol 1996, 106:273-279.
44. 44 Casselman BL, Kilgore KS, Miller BF, Warren JS: Antibodies to neutrophil cytoplasmic antigens induce monocyte chemoattractant protein-1 secretion from human monocytes. J Lab Clin Med 1995, 126:495-502.
45. 45 Ralston DR, Marsh CB, Lowe MP, Wewers MD: Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release: role of surface proteinase-3, α1-antitrypsin, and Fcγ receptors. J Clin Invest 1997, 100:1416-1424.
46. 46 Woolfson RG, Qasim FJ, Thiru S, Oliveira DBG, Neild GH, Mathieson PW: Nitric oxide contributes to tissue injury in mercuric chloride-induced autoimmunity. Biochem Biophys Res Comm 1995, 217:515-521.
47. 47 Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y: Induction of primary antiphospholipid syndrome in mice by immunzation with human monoclonal anti-cardiolipin antibody (H-3). J Clin Invest 1992, 89:1558-1563.
48. 48 Mendlovic S, Brocke S, Schoenfeld Y, Ben-Bassat M, Meshorer A, Bakimer R, Mozes E: Induction of an systemic lupus erythematosus-like disease in mice by a common anti-DNA idiotype. Proc Natl Acad Sci USA 1988, 85:2260-2264.
49. 49 Blank M, Tomer Y, Stein M, Koplovic J, Wiik A, Meroni PL, Conforti G, Shoenfeld Y: Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration. Clin Exp Immunol 1995, 102:120-130.
50. 50 Tomer Y, Gilburd B, Blank M, Lider O, Hershkoviz R, Fishman P, Zigelman R, Meroni PL, Wiik A, Shoenfeld Y: Characterization of biologically active antineutrophil cytoplasmic antibodies induced in mice. Pathogenetic role in experimental vasculitis. Arthritis Rheum 1995, 38:1375-1381.
51. 51 Damianovich M, Gilburd B, George J, Del Papa N, Afek A, Goldberg I, Kopolovic Y, Roth D, Barkai G, Meroni PL, Shoenfeld Y: Pathogenic role of anti-endothelial cell antibodies in vasculitis: An idiotypic experimental model. J Immunol 1996, 156:4946-4951.
52. 52 Béliveau A, Dagenais P, Ménard HA: Finding a valid model for antineutrophil cytoplasmic antibody-related vasculitis: comment on the article by Tomer et al and the letter by Langford and Sneller. Arthritis Rheum 1997, 40:986-990.
53. 53 Langford CA, Sneller MC: Finding a valid model for human Wegener's granulomatosis: comment on the article by Tomer et al. Arthritis Rheum 1996, 39:1262-1266.
54. 54 Jenne DE, Fröhlich L, Hummel AM, Specks U: Cloning and functional expression of the murine homologue of proteinase 3: implications for the design of murine models of vasculitis. FEBS Lett 1997, 408:187-190.
55. 55 Goldschmeding R, Cohen Tervaert JW, Gans RO, Dolman KM, van den Ende ME, Kuizinga MC, Kallenberg CG, von dem Borne AE: Different immunological specificities and disease associations of c-ANCA and p-ANCA. Neth J Med 1990, 36:114-116.
56. 56 Lucena-Fernandez F, Dalpé G, Dagenais P, Richard C, Calvert R, Boire G, Ménard HA: Detection of anti-neutrophil cytoplasmic antibodies by immunoprecipitation. Clin Invest Med 1995, 18:153-162.
57. 57 Brack A, Geisler A, Martinez-Taboada VM, Young BR, Goronzy JJ, Weyand CM: Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997, 3:530-543.
58. 58 Brack A, Rittner HL, Younge BR, Kaltschmidt C, Weyand CM, Goronzy JJ: Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 1997, 99:2842-2850.
59. 59 Rittner HL, Hafner V, Klimiuk PA, Szweda LI, Goronzy JJ, Weyand CM: Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J Clin Invest 1999, 103:1007-1013. This study confirms the reproducibility of the CGA-SCID mouse chimera and its utility for the study of cellular and molecular mechanisms of tissue injury and novel therapeutic strategies in giant cell arteritis.